Robust Adenoviral and Adeno-Associated Viral Gene Transfer to the In Vivo Murine Heart
- 2 December 2003
- journal article
- research article
- Published by Wolters Kluwer Health in Circulation
- Vol. 108 (22), 2790-2797
- https://doi.org/10.1161/01.cir.0000096487.88897.9b
Abstract
Background— Viral gene transfer to the whole heart in vivo has been achieved in several mammalian species but remained difficult to accomplish in murine hearts. We postulated that a key impediment derives from the use of proximal aortic occlusion during virus injection, because this eliminates coronary perfusion gradients in mice as aortic root and left ventricle pressures equalize. Methods and Results— Pressure-volume analysis confirmed these mechanics. In contrast, descending aortic occlusion with whole-body cooling (20°C) preserved transmyocardial perfusion gradients and allowed for sustained (>10-minute) dwell times in an upper-body perfusion circuit. This approach yielded robust cardiac transfection with adenovirus (AdV) and adeno-associated virus (AAV) injected into the left ventricle cavity or more simply via a central vein. Cardio-specific expression was achieved with a myocyte-specific promotor. Optimal AdV transfection required 9-minute aortic occlusion, versus 5-minute occlusion for AAV. Using this method, we examined the in vivo function of phospholamban (PLB) by stably transfecting PLB-null mice with AAV encoding PLB (AAVPLB). AAVPLB restored PLB protein to near control levels that colocalized with SERCA2A in cardiomyocytes. At baseline, PLB-null hearts exhibited enhanced systolic and diastolic function, but frequency-dependent reserve was blunted versus wild-type controls. These properties, particularly the frequency response, returned toward control 3 months after AAVPLB transfection. Conclusions— The new simplified approach for murine whole-heart viral transfection should assist molecular physiology studies.Keywords
This publication has 20 references indexed in Scilit:
- Chronic suppression of heart-failure progression by a pseudophosphorylated mutant of phospholamban via in vivo cardiac rAAV gene deliveryNature Medicine, 2002
- Cardiac phosphodiesterase 5 (cGMP‐specific) modulates β‐adrenergic signaling in vivo and is down‐regulated in heart failureThe FASEB Journal, 2001
- Minimal force‐frequency modulation of inotropy and relaxation of in situ murine heartThe Journal of Physiology, 2001
- Adenovirus-mediated genetic manipulation of the myocardial ß-adrenergic signaling system in transplanted heartsThe Journal of Thoracic and Cardiovascular Surgery, 2000
- Cardiovascular gene therapyThe Lancet, 2000
- Phospholamban and cardiac contractilityAnnals of Medicine, 2000
- Enhancement of cardiac function after adenoviral-mediated in vivo intracoronary β2-adrenergic receptor gene deliveryJournal of Clinical Investigation, 1999
- Acceleration of widespread adenoviral gene transfer to intact rabbit hearts by coronary perfusion with low calcium and serotoninGene Therapy, 1998
- Endothelial Nitric Oxide Synthase Targeting to CaveolaeJournal of Biological Chemistry, 1996
- Gene therapy for vascular diseasesAtherosclerosis, 1995